MALVERN, PA — Neuronetics Inc. (NASDAQ: STIM) will participate in an institutional investor conference next week, providing investors with an opportunity to hear the company’s perspective on the commercialization of emerging neuropsychiatric therapies as the mental health treatment market continues to evolve.
The company said its management team will participate in the B. Riley Securities Mind, Muscle & Vision Summit, an invitation-only event scheduled to be held in person at the InterContinental Boston.
Neuronetics is scheduled to join a panel discussion, “Commercializing the Next Wave of Novel Neuropsychiatric Drugs,” on Thursday, July 16. Compass Pathways will also participate in the discussion.
Management will also conduct one-on-one meetings with institutional investors throughout the day, the company said.
The panel discussion will not be webcast because the conference is limited to invited institutional investors.
Neuronetics develops the NeuroStar transcranial magnetic stimulation system and, through its Greenbrook clinic network, provides transcranial magnetic stimulation and SPRAVATO treatment services for patients with depression and other mental health conditions. The company’s NeuroStar system has received U.S. Food and Drug Administration clearances for multiple indications, including major depressive disorder in adults, obsessive-compulsive disorder, anxiety symptoms associated with depression, and as a first-line adjunctive treatment for major depressive disorder in patients ages 15 to 21.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.